Abstract 2299P
Background
Mebendazole (Mbz), a well-known anthelminthic drug, has been demonstrated to have anti-cancer properties in tumor models and patients. The therapeutic effect of Mbz was suggested to be due to microtubule inhibition, but more recently we reported that Mbz switches macrophages from the M2 to the tumor suppressive M1 phenotype. The aims of this study were to further investigate in tumor models the cytotoxic and immunomodulatory effects of Mbz alone, in combination with cytotoxic drugs and PD-1 antibody.
Methods
Tumor samples from patients with solid or hematological malignancies undergoing diagnostic or therapeutic procedures were obtained in accordance with ethical permission. The samples were then prepared to isolated tumor cells for ex vivo testing. Ex vivo activity of Mbz alone and in combination with standard cytotoxic drugs was assessed using the fluorometric microculture cytotoxic assay. Survival index and synergy scores were calculated using GraphPad and SynergyFinder. In vivo antitumor activity of Mbz, irinotecan, a PD-1 inhibitor and their combinations were examined in a murine BALB/c model with inoculated syngeneic colon cancer cells (CT26). Tumor growth was measured by caliper and tumors were retrieved and assessed by flow cytometry for immune cell infiltration.
Results
Mbz alone showed some modest cytotoxic activity against patient tumor cells ex vivo, with hematological tumor cells being slightly more sensitive. The cytotoxic effect of Mbz was generally additive to that of other drugs but synergistic when combined with irinotecan. In the murine model, Mbz, irinotecan and the PD-1 antibody alone inhibited tumor growth. Combined with irinotecan Mbz had an additive effect, but was synergistic when combined with the PD-1 antibody. In line with the latter observation, flow cytometry showed an increase of M1 macrophages and decrease of M2 macrophages in tumors from animals treated with the combination.
Conclusions
Mbz show promising features making it suitable for repositioning into an anti-cancer drug, most notably as a modulator of the macrophage phenotype that may enhance and the effect of check-point inhibitors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sharmineh Mansoori.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2305P - Next-generation sequencing-based regression algorithm to determine homologous recombination deficiency scores in a pan-cancer cohort
Presenter: Sejin Kim
Session: Poster session 08
2306P - How TAILORx changed treatment allocation based on 21-gene recurrence score in the daily clinic: A single center retrospective analysis
Presenter: Elena Chiru
Session: Poster session 08
2307P - Loss of CYP2D6 activity sensitizes liver cancer cells to chemotherapy
Presenter: Natallia Rameika
Session: Poster session 08
2308P - CyPep-1 reprograms the tumor microenvironment and enhances the efficacy of immune checkpoint inhibitors
Presenter: Bassam Janji
Session: Poster session 08
2309P - High DDR1 mRNA and protein expression across human tumor types correlate with epithelial composition of the tumor microenvironment
Presenter: Laura Dillon
Session: Poster session 08
2310P - Oxygen nano-bubbles attenuate hypoxia-induced tumour malignancy in tumour xenograft models
Presenter: Kumari Bhavya
Session: Poster session 08
2311P - Population pharmacokinetic-pharmacodynamic modeling to inform optimal dosing strategies for GI-101, a novel fusion protein, targeting IL2βγR and CTLA4
Presenter: Dongwoo Chae
Session: Poster session 08
2312P - SGLT2i dapagliflozin decreases NLRP3, IL-1 and PCSK9 expression in preclinical models of short-term doxorubicin cardiotoxicity
Presenter: Annamaria Bonelli
Session: Poster session 08
2313P - APOBEC mutagenesis and macrophage infiltration in cancer
Presenter: Andrea Gazzo
Session: Poster session 08
2314P - Quality and safety of research biopsies (RB) in oncology clinical trials
Presenter: Paolo Nuciforo
Session: Poster session 08